Hutchison China MediTechのSMA 200
Hutchison China MediTechのSMA 200は何ですか。
Hutchison China MediTech Ltd.のSMA 200はGBX283 -11.27%です。
SMA 200の定義は何ですか。
SMA 200は、過去200日間の終値の非加重平均として計算された過去200日間の平均株価です。
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
LSEのセクタHealth CareにおけるSMA 200の企業と比べるHutchison China MediTech
Hutchison China MediTechは何をしますか。
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Hutchison China MediTechと類似のsma 200
- Mangalam SeedsのSMA 200は₨281 -13.50%です。
- Kansai Nerolac PaintsのSMA 200は₨282 +10.73%です。
- Gallantt MetalのSMA 200は₨282 +24.88%です。
- Schroder Income Growth Fund PlcのSMA 200はGBX282 +5.08%です。
- Thirumalai ChemicalsのSMA 200は₨282 +14.21%です。
- Greenply IndustriesのSMA 200は₨282 +27.24%です。
- Hutchison China MediTechのSMA 200はGBX283 -11.27%です。
- Ashtead PlcのSMA 200は$283 -1.63%です。
- Finolex IndustriesのSMA 200は₨283 +8.05%です。
- VLS FinanceのSMA 200は₨284 +30.17%です。
- Dunedin Income Growth Investment Trust PlcのSMA 200はGBX284 -0.15%です。
- Oxford Biomedica PlcのSMA 200はGBX284 +15.15%です。
- Gallantt MetalのSMA 200は₨284 +24.35%です。